Thomas Pfeiffer (@th_pfeiffer) header
Thomas Pfeiffer (@th_pfeiffer) profile picture

Co-founder Pangea Bio, Neuroscientist, Nature-inspired Drug discovery, Biotech Entrepreneur

London, England
Joined July 2017
Photo by Thomas Pfeiffer (@th_pfeiffer)Photo by Thomas Pfeiffer (@th_pfeiffer)Photo by Thomas Pfeiffer (@th_pfeiffer)Photo by Thomas Pfeiffer (@th_pfeiffer)
Interested in prodrugs? This review in the June issue analyses approved prodrugs and discusses trends in their development, design rationales, indications, mechanisms of API release, chemistry of promoieties and market impact bit.ly/43I3X1U rdcu.be/dIGPU
3
68
5
197
28,524
The state of the art in secondary pharmacology and its impact on the safety of new medicines bit.ly/3WRAWiW This new article discusses best practices in secondary pharmacology screening, including safety-associated targets not covered by most current screening panels
20
2
88
12,953
It's #FluorescentFriday! What happens in the brain during normal aging? While most neurons will not shrink, they will lose synapses, the connections between different neurons, which can affect learning and memory. But how do we take these images from primates? (1/5)
8
174
8
847
77,377
Thomas Pfeiffer retweeted
🧠 Curious about how neurons are wired in the human cortex? Our @ScienceMagazine study tested over 7,000 connections and revealed key differences from rodents: "Directed and acyclic synaptic connectivity in the human layer 2-3 cortical microcircuit". 🧵👇science.org/doi/10.1126/scie…
6
70
11
209
45,572
Here is a data-driven reorganization of the symptoms in the DSM-5. 🧵1/10
13
180
8
912
133,622
Thomas Pfeiffer retweeted
There's never been a disease-modifying drug for Parkinson's disease to slow its progression. Now there may be two emerging. —GLP-1 nejm.org/doi/abs/10.1056/NEJ… @NEJM —anti-synuclein antibody nature.com/articles/s41591-0… @NatureMed
19
398
19
1,546
133,599
Thomas Pfeiffer retweeted
Researchers at AD/PD 2024 discussed progress in developing disease-modifying therapies for synucleinopathies. #parkinsonsdisease @adpdnet ow.ly/sPMC50RcMUi
3
6
1,930
Delighted to announce Prof David Attwell (@ucl) as Centre Director of our groundbreaking new Centre for Vascular Dementia Research, a partnership with @TheBHF!🎉👏 Prof Attwell's extensive experience brings a wealth of leadership & vision to the role👉buff.ly/3PQbDJL
1
21
2
100
8,343
Thomas Pfeiffer retweeted
We have open positions for a postdoc and a research assistant in the beautiful city of Edinburgh at the @UKDRI! Reach out if you want to know more about either of the positions!
2
43
2
72
17,999
The landscape of small-molecule prodrugs bit.ly/43I3X1U This new review analyses approved prodrugs to reveal trends in their development, highlighting design rationales, indications, mechanisms of API release, chemistry of promoieties and the market impact of prodrugs
1
79
2
272
25,329
Thomas Pfeiffer retweeted
My brand-new lab website is now LIVE! misa-arizono.com Thank you, merci, arigato to everyone who helped me get to this point.
5
16
1,084
Check out these exciting startups and the promising work they are doing to promote brain health.
📢 Today we announce the 2024 cohort of the #OneMindAccelerator program! By supporting these 10 startups, One Mind seeks to advance precision psychiatry and make quality mental healthcare accessible, affordable & equitable. Learn more: businesswire.com/news/home/2…
1
7
15
3,940
Day 1 for Pangea Bio at #ADPD2024 in Lisbon! I can't wait to discuss our lead compound OT-003's potential for treating PD and other neurodegenerative diseases. Get in touch if you wish to meet and visit us at our poster # 0530 on Friday & Saturday (lnkd.in/e3Dsqx-U).
1
5
540
Thomas Pfeiffer retweeted
Active neurons can stimulate the clearance of their own metabolic waste by driving changes to ion gradients in the surrounding fluid and by promoting the pulsation of nearby blood vessels go.nature.com/3Td6Kwe
1
94
3
369
55,869
Thomas Pfeiffer retweeted
1/🧵 Lots of fuss and bother about the announcement from @neuralink today about having implanted their tech in a human brain for the first time. bbc.co.uk/news/technology-68…
18
124
36
366
150,542
Thomas Pfeiffer retweeted
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good. acpjournals.org/doi/10.7326/… @AnnalsofIM
7
90
9
327
107,183